Berkeley Biologics Acquires Elutia’s Orthobiologics Business Unit

Berkeley Biologics Acquires Elutia’s Orthobiologics Business Unit

Elutia Inc. (previously known as Aziyo Biologics, Inc.) announced on September 18 that it divested its Orthobiologics business unit to Berkeley Biologics LLC. Mizuho Securities USA LLC acted as advisor to Elutia.   According to data captured in the LevinPro HC database, this transaction marks the 110th Biotechnology transaction of the year.   Elutia will receive cash proceeds of up to $35 million, comprising an upfront payment at closing of $15 million plus potential earnout payments of up to $20 million over a five-year period. The transaction is expected to close in the fourth quarter of 2023.   Orthobiologics are therapies that can be used by orthopaedic... Read More »
Sagaliam Acquisition Corp. Acquires Biogenysis and Virogentics 

Sagaliam Acquisition Corp. Acquires Biogenysis and Virogentics 

Enzolytics, Inc. announced on September 18 that it sold two of its wholly owned subsidiaries, Biogenysis, Inc. and Virogentics, Inc., to Sagaliam Acquisition Corp. in a transaction valued at $450 million.  Enzolytics is a Texas-based biotechnology company with both patented anti-HIV therapeutics and a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy.  Biogenysis uses proprietary techniques to produce fully human monoclonal antibodies (mAbs) against infectious diseases. The technology is currently being employed to produce monoclonal antibody therapeutics for treating the CoronaVirus... Read More »
Agilent Technologies Divests Resolution Bioscience 

Agilent Technologies Divests Resolution Bioscience 

Agilent Technologies, Inc. announced it is selling Resolution Bioscience Inc. to Exact Sciences Corp. Financial terms of the agreement were not disclosed and are not material to either party. According to data captured in the LevinPro HC database, this transaction represents the 108th Biotechnology acquisition of 2023.   Resolution Bioscience is dedicated to developing a highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients around the world. The company has developed and patented core technology for circulating cell-free DNA NGS analysis.  Exact Sciences is a molecular diagnostics company which focuses on the early... Read More »
Berkeley Biologics Acquires Elutia’s Orthobiologics Business Unit

Agios Pharmaceuticals Acquires Alnylam’s siRNA Blood Disease Program 

Agios Pharmaceuticals Inc. announced its acquisition of Alnylam Pharmaceuticals, Inc.’s siRNA blood disease program targeting TMPRSS6, a gene that makes protein. According to data captured in the LevinPro HC database, this transaction marks the 105th Biotechnology acquisition in 2023.    Alnylam is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002. According to its most recent financial report, the company achieved net product revenues of $894 million during FY 2022.  Agios is the pioneering leader in pyruvate kinase (PK) activation... Read More »
Agilent Technologies Divests Resolution Bioscience 

Cybin Acquires Small Pharma 

Cybin, Inc. announced on August 28 its acquisition of Small Pharma, Inc. a London-based biotechnology company progressing a pipeline of short-duration psychedelic-assisted therapies for the treatment of mental health conditions.  Small Pharma has a portfolio of clinical-stage DMT-based assets, SPL026 and SPL028. Small Pharma was granted an Innovation Passport designation for SPL026 from the U.K. Medicines and Healthcare products Regulatory Agency and has a pipeline of proprietary preclinical assets.  Cybin is a biopharmaceutical company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Headquartered in Toronto and founded in... Read More »
Agilent Technologies Divests Resolution Bioscience 

Cell Microsystems Acquires Fluxion Biosciences 

Durham, North Carolina-based Cell Microsystems announced its acquisition of Fluxion Biosciences. According to data captured in the LevinPro HC database, this acquisition represents the 102nd Biotechnology transaction of 2023, and 19th in the third quarter.    Fluxion delivers advanced solutions that automate complex cell-based and cell-free assays. Products include ERASE-Seq for NGS analysis of cancer from a “liquid biopsy” blood sample, IsoFlux for circulating tumor cell analysis, BioFlux for functional analysis of cellular interactions and the IonFlux automated patch clamp system.  Cell Microsystems provides pioneering solutions for cell biology research, and... Read More »